1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
TREATMENT OF PREMENSTRUAL SYNDROME BY SPIRONOLACTONE
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1979.tb10582.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 86, Issue 2, pages 142–147, February 1979
Additional Information
How to Cite
Shaughn O'Brien, P. M., Craven, D., Selby, C. and Symonds, E. M. (1979), TREATMENT OF PREMENSTRUAL SYNDROME BY SPIRONOLACTONE. BJOG: An International Journal of Obstetrics & Gynaecology, 86: 142–147. doi: 10.1111/j.1471-0528.1979.tb10582.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
Spironolactone was given to 28 women in a double blind cross over trial during four menstrual cycles. Hormonal profiles were measured during the first two cycles. Plasma aldosterone was elevated in the premenstrual phase of the cycles but there was no significant difference between symptomatic and asymptomatic groups. The rise in serum progesterone was higher in the symptomatic group during the postovulatory phase. The administration of spironolactone reduced weight and relieved psychological symptoms in more than 80 per cent of the symptomatic group.